IDH1 and acute myeloid leukemia: Ivosidenib monotherapy given orally at 500 mg daily was evaluated in a phase 1 dose escalation cohort of 179 patients with R/R AML with an IDH1 mutation (NCT02074839; study started March 2014) [8].